Table of Contents
ISRN Molecular Biology
Volume 2012 (2012), Article ID 170676, 9 pages
http://dx.doi.org/10.5402/2012/170676
Research Article

Receptor Binding by Cholera Toxin B-Subunit and Amino Acid Modification Improves Minimal Peptide Immunogenicity

1Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 82 Stockholm, Sweden
2Division of Education and Research administration, Mälardalen University, P.O. Box 883, 721 23 Västerås, Sweden
3Etvax AB, Gunnar Asplunds Alle 16, 171 63 Solna, Sweden
4Institution of Clinical and Experimental Medicine, Linköping University, 581 83 Linköping, Sweden

Received 12 April 2012; Accepted 20 May 2012

Academic Editors: H. Hashimoto and I. Kim

Copyright © 2012 Andreas Boberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. G. Deeks, “Transmitted minority drug-resistant HIV variants: a new epidemic?” PLoS Medicine, vol. 5, no. 7, p. e164, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Tozzi, A. Corpolongo, R. Bellagamba, and P. Narciso, “Managing patients with sexual transmission of drug-resistant HIV,” Sexual Health, vol. 2, no. 3, pp. 135–142, 2005. View at Google Scholar · View at Scopus
  3. D. Turner and M. A. Wainberg, “HIV transmission and primary drug resistance,” AIDS Reviews, vol. 8, no. 1, pp. 17–23, 2006. View at Google Scholar · View at Scopus
  4. C. A. B. Boucher, A. M. J. Wensing, R. Schuurman, D. A. M. C. van de Vijver, A. I. Stolwijk, and M. Toet, “Transmission of drug-resistant HIV-1 in Europe remains limited to single classes,” AIDS, vol. 22, no. 5, pp. 625–635, 2008. View at Google Scholar
  5. A. M. J. Wensing, D. A. van de Vijver, G. Angarano, B. Asjo, C. Balotta, E. Boeri et al., “Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management,” The Journal of Infectious Diseases, vol. 192, no. 6, pp. 958–966, 2005. View at Google Scholar
  6. A. Boberg, S. Dominici, A. Brave et al., “Immunization with HIV protease peptides linked to syngeneic erythrocytes,” Infectious Agents and Cancer, vol. 2, article 9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Boberg, D. Sjöstrand, E. Rollman, J. Hinkula, B. Zuber, and B. Wahren, “Immunological cross-reactivity against a drug mutated HIV-1 protease epitope after DNA multi-CTL epitope construct immunization,” Vaccine, vol. 24, no. 21, pp. 4527–4530, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Boberg and M. Isaguliants, “Vaccination against drug resistance in HIV infection,” Expert Review of Vaccines, vol. 7, no. 1, pp. 131–145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Boberg, S. Gaunitz, A. Bråve, B. Wahren, and N. Carlin, “Enhancement of epitope-specific cellular immune responses by immunization with HIV-1 peptides genetically conjugated to the B-subunit of recombinant cholera toxin,” Vaccine, vol. 26, no. 40, pp. 5079–5082, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Czerkinsky, M. W. Russell, N. Lycke, M. Lindblad, and J. Holmgren, “Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues,” Infection and Immunity, vol. 57, no. 4, pp. 1072–1077, 1989. View at Google Scholar · View at Scopus
  11. J. Holmgren, J. Adamsson, F. Anjuère et al., “Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA,” Immunology Letters, vol. 97, no. 2, pp. 181–188, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Lebens, J. B. Sun, H. Sadeghi et al., “A mucosally administered recombinant fusion protein vaccine against schistosomiasis protecting against immunopathology and infection,” Vaccine, vol. 21, no. 5-6, pp. 514–520, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. B. T. M. Korber, C. Brander, B. F. Haynes, R. Koup, J. P. Moore, B. D. Walker et al., HIV Molecular Immunology 2006/2007, Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, New Mexico, 2007.
  14. A. C. Karlsson, J. M. Chapman, B. D. Heiken et al., “Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol,” Journal of Virology, vol. 81, no. 20, pp. 11543–11548, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. C. Karlsson, S. G. Deeks, J. D. Barbour et al., “Dual pressure from antiretroviral therapy and cell-mediated immune response on the human immunodeficiency virus type 1 protease gene,” Journal of Virology, vol. 77, no. 12, pp. 6743–6752, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Lebens, S. Johansson, J. Osek, M. Lindblad, and J. Holmgren, “Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines,” Nature Biotechnology, vol. 11, no. 13, pp. 1574–1578, 1993. View at Google Scholar · View at Scopus
  17. D. Eisenberg, R. M. Weiss, and T. C. Terwilliger, “The hydrophobic moment detects periodicity in protein hydrophobicity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 1, pp. 140–144, 1984. View at Google Scholar · View at Scopus
  18. S. Pascolo, N. Bervas, J. M. Ure, A. G. Smith, F. A. Lemonnier, and B. Pérarnau, “HLA-A2.1-restricted education and cytolytic activity of CD8+ T lymphocytes from β2 microglobulin (β2m) HLA-A2.1 monochain transgenic H-2Dbβ2m double knockout mice,” The Journal of Experimental Medicine, vol. 185, no. 12, pp. 2043–2051, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Borrow, H. Lewicki, B. H. Hahn, G. M. Shaw, and M. B. A. Oldstone, “Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection,” Journal of Virology, vol. 68, no. 9, pp. 6103–6110, 1994. View at Google Scholar · View at Scopus
  20. R. A. Koup, J. T. Safrit, Y. Cao et al., “Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome,” Journal of Virology, vol. 68, no. 7, pp. 4650–4655, 1994. View at Google Scholar · View at Scopus
  21. J. T. Safrit, C. A. Andrews, T. Zhu, D. D. Ho, and R. A. Koup, “Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope,” The Journal of Experimental Medicine, vol. 179, no. 2, pp. 463–472, 1994. View at Google Scholar · View at Scopus
  22. J. E. Schmitz, M. J. Kuroda, S. Santra et al., “Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes,” Science, vol. 283, no. 5403, pp. 857–860, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Julg, K. L. Williams, S. Reddy et al., “Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses,” Journal of Virology, vol. 84, no. 11, pp. 5540–5549, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Kiepiela, K. Ngumbela, C. Thobakgale et al., “CD8+ T-cell responses to different HIV proteins have discordant associations with viral load,” Nature Medicine, vol. 13, no. 1, pp. 46–53, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Eriksson, M. Fredriksson, I. Nordström, and J. Holmgren, “Cholera toxin and its B subunit promote dendritic cell vaccination with different influences on Th1 and Th2 development,” Infection and Immunity, vol. 71, no. 4, pp. 1740–1747, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. A. George-Chandy, K. Eriksson, M. Lebens, I. Nordström, E. Schön, and J. Holmgren, “Cholera toxin B subunit as a carrier molecule promotes antigen presentation and increases CD40 and CD86 expression on antigen-presenting cells,” Infection and Immunity, vol. 69, no. 9, pp. 5716–5725, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Badizadegan, H. E. Wheeler, Y. Fujinaga, and W. I. Lencer, “Trafficking of cholera toxin-ganglioside GM1 complex into Golgi and induction of toxicity depend on actin cytoskeleton,” American Journal of Physiology, vol. 287, no. 5, pp. C1453–C1462, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. P. I. H. Bastiaens, I. V. Majoul, P. J. Verveer, H. D. Söling, and T. M. Jovin, “Imaging the intracellular trafficking and state of the AB5 quaternary structure of cholera toxin,” The EMBO Journal, vol. 15, no. 16, pp. 4246–4253, 1996. View at Google Scholar · View at Scopus
  29. Y. Fujinaga, A. A. Wolf, C. Rodighiero et al., “Gangliosides that associate with lipid rafts mediate transport of cholera and related toxins from the plasma membrane to endoplasmic reticulm,” Molecular Biology of the Cell, vol. 14, no. 12, pp. 4783–4793, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Holmgren, N. Lycke, and C. Czerkinsky, “Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems,” Vaccine, vol. 11, no. 12, pp. 1179–1184, 1993. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Lycke, “From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance,” Immunology Letters, vol. 97, no. 2, pp. 193–198, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Nikolic-Zugic and F. R. Carbone, “Peptide presentation by class-I major histocompatibility complex molecules,” Immunologic Research, vol. 10, no. 1, pp. 54–65, 1991. View at Google Scholar · View at Scopus